• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高密度脂蛋白(HDL)相关的1-磷酸鞘氨醇(S1P)与冠状动脉支架内再狭窄之间的关系。

The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis.

作者信息

Jing Xiao-Dong, Wei Xiao-Ming, Deng Song-Bai, Du Jian-Lin, Liu Ya-Jie, She Qiang

机构信息

Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

Clin Chim Acta. 2015 Jun 15;446:248-52. doi: 10.1016/j.cca.2015.04.038. Epub 2015 May 8.

DOI:10.1016/j.cca.2015.04.038
PMID:25958848
Abstract

BACKGROUND

High-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) contributed to several beneficial effects in the cardiovascular system. We explored the relationship between the HDL-S1P concentrations and coronary in-stent restenosis (ISR).

METHODS

Fifty consecutive patients with ISR and 50 normal control subjects were included. The serum S1P, HDL-S1P and clinical data were collected to explore the relationships between these parameters and ISR.

RESULTS

The patients with ISR had significantly lower concentrations of serum S1P (96.10 ± 26.33 vs. 113.40 ± 32.72; P = 0.004) and HDL-S1P (32.81 ± 10.02 vs. 42.72 ± 11.75; P < 0.001). All included patients were divided into four quartiles based on their concentrations of HDL-S1P: Quartile 1 (18.63-28.51 ng/ml), Quartile 2 (28.62-37.28 ng/ml), Quartile 3 (37.35-45.27 ng/ml), and Quartile 4 (45.59-79.36 ng/ml). The rates of ISR were 84%, 48%, 40% and 28%, respectively. The patients in Quartile 1 exhibited significantly higher rates of ISR compared with the other groups (P = 0.001). A multivariate stepwise logistic regression analysis indicated that HDL-S1P (OR = 0.846, 95% CI = 0.767-0.932, P = 0.001) was an independent predictor of ISR. An ROC analysis indicated that HDL-S1P = 30.37 ng/ml and had a 90% sensitivity and a 52% specificity in predicting ISR.

CONCLUSIONS

HDL-S1P is an independent predictor of ISR, and patients with higher concentrations of HDL-S1P have a low risk of ISR.

摘要

背景

高密度脂蛋白(HDL)相关的1-磷酸鞘氨醇(S1P)对心血管系统有多种有益作用。我们探讨了HDL-S1P浓度与冠状动脉支架内再狭窄(ISR)之间的关系。

方法

纳入50例连续的ISR患者和50例正常对照者。收集血清S1P、HDL-S1P及临床资料,以探讨这些参数与ISR之间的关系。

结果

ISR患者的血清S1P浓度(96.10±26.33对113.40±32.72;P = 0.004)和HDL-S1P浓度(32.81±10.02对42.72±11.75;P < 0.001)显著降低。根据HDL-S1P浓度将所有纳入患者分为四个四分位数:四分位数1(18.63 - 28.51 ng/ml)、四分位数2(28.62 - 37.28 ng/ml)、四分位数3(37.35 - 45.27 ng/ml)和四分位数4(45.59 - 79.36 ng/ml)。ISR发生率分别为84%、48%、40%和28%。四分位数1的患者与其他组相比,ISR发生率显著更高(P = 0.001)。多因素逐步逻辑回归分析表明,HDL-S1P(OR = 0.846,95%CI = 0.767 - 0.932,P = 0.001)是ISR的独立预测因子。ROC分析表明,HDL-S1P = 30.37 ng/ml,在预测ISR时敏感性为90%,特异性为52%。

结论

HDL-S1P是ISR的独立预测因子,HDL-S1P浓度较高的患者ISR风险较低。

相似文献

1
The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis.高密度脂蛋白(HDL)相关的1-磷酸鞘氨醇(S1P)与冠状动脉支架内再狭窄之间的关系。
Clin Chim Acta. 2015 Jun 15;446:248-52. doi: 10.1016/j.cca.2015.04.038. Epub 2015 May 8.
2
Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading.载脂蛋白高密度脂蛋白缺陷导致的冠状动脉疾病:通过鞘氨醇-1-磷酸加载进行纠正。
J Am Coll Cardiol. 2015 Sep 29;66(13):1470-85. doi: 10.1016/j.jacc.2015.07.057.
3
Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease.血浆和高密度脂蛋白中的神经鞘氨醇 1-磷酸水平在冠状动脉疾病中发生改变。
Basic Res Cardiol. 2010 Nov;105(6):821-32. doi: 10.1007/s00395-010-0112-5. Epub 2010 Jul 21.
4
HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis.高密度脂蛋白结合的1-磷酸鞘氨醇(S1P)可预测冠状动脉粥样硬化的严重程度。
Cell Physiol Biochem. 2014;34(1):172-84. doi: 10.1159/000362993. Epub 2014 Jun 16.
5
Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins.高密度脂蛋白(HDL)相关的1-磷酸鞘氨醇与血清HDL胆固醇及载脂蛋白水平的相关性。
Atherosclerosis. 2005 Jan;178(1):199-205. doi: 10.1016/j.atherosclerosis.2004.08.024.
6
Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans.血清鞘氨醇 -1- 磷酸浓度与人类动脉粥样硬化疾病呈负相关。
PLoS One. 2016 Dec 14;11(12):e0168302. doi: 10.1371/journal.pone.0168302. eCollection 2016.
7
The association of red cell distribution width with in-stent restenosis in patients with stable coronary artery disease.稳定型冠状动脉疾病患者红细胞分布宽度与支架内再狭窄的相关性
Platelets. 2015;26(1):48-52. doi: 10.3109/09537104.2014.881990. Epub 2014 May 15.
8
Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P).高密度脂蛋白(HDL)相关的鞘氨醇-1-磷酸(S1P)的抗动脉粥样硬化作用。
Cardiovasc Res. 2014 Aug 1;103(3):395-404. doi: 10.1093/cvr/cvu136. Epub 2014 Jun 1.
9
[Measurement of sphingosine 1-phosphate as a biomarker of atherosclerosis].[测定1-磷酸鞘氨醇作为动脉粥样硬化的生物标志物]
Rinsho Byori. 2007 Apr;55(4):358-62.
10
Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate.利用血清1-磷酸鞘氨醇预测阻塞性冠状动脉疾病
Am Heart J. 2003 Jul;146(1):62-8. doi: 10.1016/S0002-8703(03)00118-2.

引用本文的文献

1
The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target.鞘氨醇-1-磷酸和鞘氨醇激酶1在癌症耐药中的新作用:一个有前景的治疗靶点。
Cancer Cell Int. 2024 Feb 28;24(1):89. doi: 10.1186/s12935-024-03221-8.
2
HDL and Lipid Metabolism.高密度脂蛋白与脂代谢。
Adv Exp Med Biol. 2022;1377:49-61. doi: 10.1007/978-981-19-1592-5_4.
3
Fetal High-Density Lipoproteins: Current Knowledge on Particle Metabolism, Composition and Function in Health and Disease.胎儿高密度脂蛋白:关于健康与疾病中颗粒代谢、组成及功能的当前认知
Biomedicines. 2021 Mar 30;9(4):349. doi: 10.3390/biomedicines9040349.
4
Lysolipids in Vascular Development, Biology, and Disease.溶血磷脂在血管发育、生物学和疾病中的作用。
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):564-584. doi: 10.1161/ATVBAHA.120.305565. Epub 2020 Dec 17.
5
Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial.G 蛋白偏向性鞘氨醇-1-磷酸受体 1 激动剂 SAR247799 对 2 型糖尿病大鼠的内皮保护作用及一项随机安慰剂对照患者试验。
Br J Clin Pharmacol. 2021 May;87(5):2303-2320. doi: 10.1111/bcp.14632. Epub 2020 Nov 26.
6
Predictive value of serum CTRP9 and STIM1 for restenosis after cerebrovascular stent implantation and its relationship with vasoactive substances and inflammatory cytokines.血清CTRP9和STIM1对脑血管支架植入术后再狭窄的预测价值及其与血管活性物质和炎性细胞因子的关系。
Exp Ther Med. 2020 Sep;20(3):2617-2622. doi: 10.3892/etm.2020.9104. Epub 2020 Aug 6.
7
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.单次及多次口服 SAR247799(一种用于内皮保护的选择性 G 蛋白偏向型 1 -磷酸鞘氨醇受体 -1 激动剂)的安全性、耐受性、药代动力学和药效学的人体首次研究。
Br J Clin Pharmacol. 2021 Feb;87(2):598-611. doi: 10.1111/bcp.14422. Epub 2020 Jul 8.
8
Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases.新型见解:高密度脂蛋白相关神经酰胺-1-磷酸在心脏代谢疾病中的作用。
Int J Mol Sci. 2019 Dec 12;20(24):6273. doi: 10.3390/ijms20246273.
9
Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis.高尿酸血症对经皮冠状动脉介入治疗支架内再狭窄后临床结局的影响。
BMC Cardiovasc Disord. 2018 Jun 11;18(1):114. doi: 10.1186/s12872-018-0840-2.
10
Pharmacological Intervention to Modulate HDL: What Do We Target?调节高密度脂蛋白的药理学干预:我们的目标是什么?
Front Pharmacol. 2018 Jan 22;8:989. doi: 10.3389/fphar.2017.00989. eCollection 2017.